Who's making what, pipeline deals, shortages, and supply shifts — the business moves that change availability and price.
The Trump administration has brokered a significant deal with Eli Lilly and Novo Nordisk to lower the cost of weight loss drugs for Medicare beneficiaries. Under the agreement, the list prices for Wegovy and Zepbound will drop to approximately $250 per month, with a $50 copay for patients. In exchange, Medicare plans will be required to cover these GLP-1 treatments for weight loss in high-risk individuals, marking a shift in federal policy regarding obesity medication coverage.
STAT reports that Novo Nordisk previously shelved a promising triple agonist targeting GLP-1, GIP, and glucagon due to safety concerns, allowing Eli Lilly to advance its own candidate, retatrutide. While Novo focused on semaglutide (Wegovy), the decision highlights a conservative corporate culture that may have cost them their lead in the obesity market as retatrutide progresses through late-stage trials.
Novo Nordisk has priced its newly approved oral Wegovy pill at $299 per month for direct-to-consumer cash sales, undercutting Eli Lilly's planned price of $399 for its competing oral agent orforglipron. This pricing strategy places the pill below the cost of current injectable versions of Wegovy and Zepbound, aiming to secure market share among uninsured patients. The move highlights an intensifying focus on the oral obesity market as manufacturers compete on price and convenience.
Major employers like HCA Healthcare are removing coverage for obesity drugs Wegovy and Zepbound due to surging costs, instead directing employees to manufacturer-sponsored cash-pay programs. While Eli Lilly and Novo Nordisk market these direct-to-consumer options as expanded access, experts warn they effectively allow companies to offload the financial burden onto workers. This shift highlights a growing tension where corporate cost-cutting strategies may render these essential peptide treatments unaffordable for the patients who need them.
Health Secretary Robert F. Kennedy Jr. publicly endorsed the Trump administration's deal to lower prices and expand access to GLP-1 weight loss drugs, marking a significant shift from his previous skepticism. The agreement aims to include Medicare and Medicaid coverage for medications produced by Eli Lilly and Novo Nordisk. Kennedy described the drugs as a 'tool' rather than a 'silver bullet,' surprising many supporters of his 'Make America Healthy Again' movement who expected him to oppose pharmaceutical interventions.
Medicare is preparing to offer weight loss coverage for GLP-1 drugs like Wegovy and Zepbound starting in July 2026, with a patient copay of $50. However, the Centers for Medicare and Medicaid Services (CMS) has not released data estimating the total cost to taxpayers for this new benefit. The lack of financial transparency comes despite the fact that taxpayers will fund the majority of the expenses for these high-cost therapies.
A new analysis indicates that generic versions of semaglutide, the active ingredient in Wegovy and Ozempic, could be manufactured for as little as $3 per month. Researchers estimate production costs between $28 and $140 annually, suggesting significant potential for increased access in low- and middle-income countries as patents begin to expire in key markets like India and Brazil.
Novo Nordisk has settled a patent infringement lawsuit against telehealth company Hims & Hers regarding the sale of compounded Wegovy. As part of the agreement, Hims will cease advertising compounded GLP-1 products but will continue to offer them if deemed clinically necessary by a provider. Additionally, Hims will now list brand-name Wegovy on its platform, marking a shift in its business strategy.
Medicare drug spending is rising faster than anticipated, largely due to the surging utilization of GLP-1 medications. This trend is occurring alongside the financial impacts of the Democrats' redesign of Part D drug coverage. The increased cost burden highlights the growing influence of peptide-based weight loss drugs on federal healthcare budgets.
The U.S. government is launching a demonstration program to make obesity drugs, such as GLP-1 receptor agonists, available to Medicare beneficiaries for the first time. This initiative, named the Bridge program, circumvents the statutory ban on Medicare coverage for obesity treatments by utilizing a temporary coverage model. The move follows resistance from private insurers regarding a previously proposed voluntary coverage structure.
A STAT Plus analysis reports that U.S. health spending experienced a significant increase in 2025, driven largely by the utilization of GLP-1 medications and a general rise in the demand for healthcare services. The report identifies the widespread adoption of these weight-loss and diabetes drugs as a primary factor behind the sharp financial escalation.
On May 21, 2026, Eli Lilly reported that its triple-agonist candidate retatrutide delivered up to 28% mean weight loss among treatment completers on the 12 mg dose in the pivotal TRIUMPH-1 Phase 3 trial, which randomized roughly 2,339 people with obesity and followed them over 80 weeks. The 'triple-G' molecule — targeting GLP-1, GIP, and glucagon receptors — is positioned as a potential best-in-class challenger to semaglutide and tirzepatide. Lower-dose arms achieved about 26% (9 mg) and 19% (4 mg) mean weight loss versus 2% for placebo, and the positive topline readout was flagged as a new high-water mark for the obesity pipeline.
Industry analysts peg the peptide therapeutics market at roughly $54B in 2026, growing at a ~6.8% CAGR toward an estimated $85B by 2033 — driven largely by GLP-1 receptor agonists and a broadening pipeline. (Vendor market-research source — verify independently.)
On November 4, 2025, contract manufacturer CordenPharma announced a more than €500 million greenfield peptide manufacturing facility at Getec Park in Muttenz, Switzerland (canton of Basel-Landschaft), designed for small-, medium-, and large-scale peptide development and production using SPPS reactors with combined capacity exceeding 5,000 liters. The plant — part of a broader >€1 billion, multi-year expansion across Europe and the U.S. — is expected to create over 300 jobs and underpins a strategic target of more than €1 billion in peptide-business sales by 2028. The investment is the latest in a wave of peptide-CDMO capacity build-outs chasing GLP-1 demand.
On May 7, 2025, Novo Nordisk lowered its full-year 2025 forecast, trimming sales-growth guidance by roughly 3 percentage points and operating-profit guidance by about 5 percentage points, citing weaker-than-planned U.S. market penetration and continued competition from lower-priced compounded semaglutide copies. CEO Lars Fruergaard Jørgensen said the company was 'actively focused on preventing unlawful and unsafe compounding' even as the cheaper alternatives eroded near-term Wegovy and Ozempic uptake. The guidance cut punctuated a sharp deceleration in GLP-1 growth rates and preceded further price actions later in the year.
On February 21, 2025, the FDA issued a Declaratory Order officially determining that the shortage of semaglutide injection products — the active ingredient in Novo Nordisk's Ozempic and Wegovy — is resolved, removing it from the agency's 506e shortage list where it had sat since 2022. The order triggers a wind-down of the large compounding-pharmacy market that sprang up around copycat GLP-1 injections, with enforcement-discretion deadlines of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. The move reshapes the U.S. GLP-1 supply landscape after three years of scarcity-driven alternatives.